New drug trial aims to tackle heart and metabolic risks in black community
NCT ID NCT06320951
First seen Jan 27, 2026 · Last updated May 01, 2026 · Updated 17 times
Summary
This study tests whether vericiguat, a drug that boosts a natural signaling molecule called cGMP, can improve how the body uses insulin and burns energy in Black adults with obesity and insulin resistance. Researchers will give the drug or a placebo to 200 participants for 12 weeks and measure changes in insulin sensitivity, energy expenditure, and fat tissue activity. The goal is to find a new way to reduce heart and metabolic disease risk in this population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
Conditions
Explore the condition pages connected to this study.